← Back to Patent Explorer
US4478816A Expired / Lapsed US ⏱️ 0.0 years remaining

Rare earth/chelating agent complex for digital fluoroscopy

Assignee: Georgetown University
•
Filing: 1982-06-07
•
Granted: 1984-10-23
•
Expires: 2002-06-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A rare earth/chelating agent complex is employed in digital fluoroscopy. More specifically, a contrast medium is utilized in digital fluoroscopy, the contrast medium consisting of a non-radioactive composition of a rare earth metal and a chelating agent. The rare earth metal is lutecium or ytterbium, while the chelating agent is DTPA, EHPG or HBED. The digital fluoroscopy method results in the development of diagnostic energy difference image information as a result of application of X-ray beams of two different energy levels, coupled with subtraction processing of the resulting image information.

Inventors

  • 👤 Robert S. Ledley
  • 👤 Edward J. Zapolski

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-26 03:34
CPC Classifications
A; A61; A61K; A61K49/00; A61K49/04

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 94 words
A method of obtaining diagnostic energy difference image information of a patient, comprising the steps of: (a) injecting a sterile aqueous solution comprising an effective amount of a non-radioactive rare earth metal and a chelating agent into the patient intraveneously; (b) applying an X-ray beam having a first energy level to the paitent to obtain first image information; (c) applying an X-ray beam having second energy level to the patient to obtain a second image information; and (d) subtraction processing the first and second image informations to obtain the diagnostic energy difference image information.
Claim 2
Independent Claim 94 words
A method of obtaining diagnostic energy difference image information of a patient, comprising the steps of: (a) injecting a sterile aqueous solution comprising an effective amount of a non-radioactive rare earth metal and a chelating agent into the patient intraveneously; (b) applying an X-ray beam having a first energy level to the paitent to obtain first image information; (c) applying an X-ray beam having second energy level to the patient to obtain a second image information; and (d) subtraction processing the first and second image informations to obtain the diagnostic energy difference image information.
Claim 3
Dependent Claim 16 words
The method of claim 1, further comprising step (e) of displaying the energy difference image information.
Claim 4
Dependent Claim 20 words
The method of claim 1, wherein said rare earth metal is selected from the class consisting of lutetium and ytterbium.
Claim 5
Dependent Claim 13 words
The method of claim 1, wherein said chelating agent is diethylenetriamine pentaacetic acid.
Claim 6
Dependent Claim 13 words
The method of claim 1, wherein said chelating agent is ethylenediamine-N,N'-bis (2-hydroxy-phenylacetic acid).
Claim 7
Dependent Claim 14 words
The method of claim 1, wherein said chelating agent is N,N'-bis (2-hydroxbenzyl) ethylene-diamine-N,N'-diacetic acid.

References Cited (Backward Citations)

US3480715A Cited
US3663688A Cited
US4017596A Cited
US3995020A Cited
US4176173A Cited
US4283382A Cited
US4310507A Cited
US4192859A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1987-10-23 1988-04-23 1988-10-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1991-10-23 1992-04-23 1992-10-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1995-10-23 1996-04-23 1996-10-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag